Dr Eleni Efstathiou (MD Anderson Cancer Center, Houston, USA) chairs a discussion with Prof Kurt Miller (Benjamin Franklin University Clinic, Berlin, Germany), Dr Chris Parker (The Royal Marsden, London, UK) and Prof Stephane Oudard (Hopital European Georges Pompidou, Paris, France).
Reflecting on the prostate cancer data presented at ASCO 2016, the panel covers potentially practice changing results for how we approach biopsy and the questions that have been raised for sequencing versus combination.
The PROMIS study showed how multi-parametric magnetic resonance imaging (MP-MRI) as a triage test can prevent men from undergoing unnecessary biopsy, without impairing the detection of clinically significant cancer.
The panel agreed that whilst this looks set to be the future, radiologist training is paramount to its successful adoption in a clinical setting.
Amongst other highlights of ASCO 2016, the panel discussed the study that covered neoadjuvant enzalutamide (ENZA) and abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus AA LHRHa in localised high-risk prostate cancer (LHRPC).
The findings do not favour adding ENZA to augment AA LHRHa efficacy in LHRPC, but did emphasise the need to consider biologic heterogeneity when applying AR targeting therapies.
The advances seen at ASCO 2016 in how prostate cancer is treated provide plenty of encouragement for the PC community, with the successes seen sure to be built on in the coming years.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).